Rebecca Ezell
Family · Slidell, LANPI 1205333622
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $190,073 of the $268,061 with a category attached, or 70.9%. AstraZeneca accounts for 70.7% of it on its own, with 33 other manufacturers making up the rest. 2025 is the largest year on record at $154,094, more than ten times the $2,565 reported in 2021. Among family clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,290 payments — averaging $207.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$190K
- Regeneron Healthcare Solutions, Inc.$35K
- Sanofi$29K
- GSK$8K
- Regeneron$1K
- Boehringer Ingelheim$1K
- plus $4K from 28 others
What the payments were for
- Consulting fees$5,7902%
- Speaking & faculty fees$190,07371%
- Travel & lodging$43,52916%
- Food & beverage$28,63411%
- Education$340%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 569 | $189,640 |
| Regeneron Healthcare Solutions, Inc. | 156 | $35,379 |
| Sanofi | 90 | $28,541 |
| GSK | 208 | $7,578 |
| Regeneron | 2 | $1,392 |
| Boehringer Ingelheim | 48 | $1,220 |
| Grifols USA, LLC | 36 | $887 |
| Baxter Healthcare | 30 | $626 |
| Mylan Specialty L.p. | 25 | $440 |
| United Therapeutics Corporation | 14 | $361 |
| Electromed, Inc. | 34 | $360 |
| Inspire Medical Systems, Inc. | 4 | $247 |
| Advanced Respiratory, Inc | 10 | $141 |
| Merck | 7 | $141 |
| ANI Pharmaceuticals, Inc. | 6 | $141 |
| Amgen | 6 | $132 |
| Paratek Pharmaceuticals, Inc. | 7 | $125 |
| Pfizer | 8 | $124 |
| Tactile Systems Technology Inc | 3 | $76 |
| Sunovion Pharmaceuticals Inc. | 3 | $62 |
| Verona Pharma, Inc. | 3 | $62 |
| Actelion Pharmaceuticals US, Inc. | 3 | $60 |
| Viatris Specialty LLC | 2 | $58 |
| Philips North America LLC | 3 | $43 |
| Novartis | 2 | $36 |
| AbbVie | 2 | $32 |
| Bayer | 2 | $27 |
| Vifor Pharma, Inc. | 1 | $27 |
| Mallinckrodt Hospital Products Inc. | 1 | $27 |
| Insmed, Inc. | 1 | $19 |
| Lilly USA, LLC | 1 | $17 |
| Apria Healthcare LLC | 1 | $15 |
| Pulmonx Corporation | 1 | $13 |
| Inogen, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$268,061 in reported general payments places this provider in the 95th percentile of 3,610 family providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 603 | $677,483 |
| NucalaMepolizumab | 157 | $577,372 |
| Fasenra PenBenralizumab | 87 | $460,835 |
| OfevNintedanib Esylate | 32 | $417,771 |
| TezspireTezepelumab-Ekko | 74 | $309,028 |
| Dupixent PenDupilumab | 80 | $292,270 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 248 | $209,900 |
| Dupixent SyringeDupilumab | 42 | $159,247 |
| Breo ElliptaFluticasone/Vilanterol | 105 | $56,567 |
| Advair HfaFluticasone Propion/Salmeterol | 60 | $29,920 |
| EliquisApixaban | 32 | $22,496 |
| SymbicortBudesonide/Formoterol Fumarate | 74 | $21,405 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 505 | $18,888 |
| Spiriva RespimatTiotropium Bromide | 32 | $18,259 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 27 | $15,635 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Arnuity Ellipta | $7,578 | $1,313,646876 claims |
| AstraZenecaTezspire, Breztri Aerosphere, Symbicort | $189,640 | $540,333396 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat | $1,220 | $463,692111 claims |
| PfizerEliquis | $124 | $22,49632 claims |
| MerckDulera | $141 | $10,32326 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,610 family providers in Louisiana.
Other family in Slidell
- Shelley MaillhoSlidell$60K
- Miyagi HendersonSlidell$13K
- Lindsay PonsteinSlidell$12K
- Erin PierceNew Orleans$261K
- Tavell KindallNew Orleans$194K
- Ashlea HillRuston$169K
- Brittany MillerVille Platte$158K
- Ryanne ClarkeGretna$123K
- Elidia DewittBaton Rouge$108K
- Rebekah GarrardLafayette$105K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.